Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Broader Medicare Coverage For Leqembi Begins As CMS-Backed Registry Opens For Business

Executive Summary

There is no fee to participate, and entries to the registry must be made at baseline and then every six months for up to two years.

You may also be interested in...

Medicare’s Registry Plans For Leqembi Prompt New Calls For Transparency, Rigor

Now that it’s clear the Centers for Medicare and Medicaid Services is moving ahead with the patient registry requirement for the Alzheimer’s drug, experts weigh in on how best to collect useful information.    

New Alzheimer’s Drug Access Should Ease Somewhat Under Updated Medicare PET Scan Proposal

After a decade of curtailed use, new drugs make wider availability important for patient selection and safety, CMS says in a new amyloid PET scan proposal. 

New Model For Real World Evidence? Leqembi Registry Data Will Be Bolstered By Medicare Claims

Senior Centers for Medicare and Medicaid Services official Lee Fleisher described the game plan behind the CMS-facilitated patient registry for the new Alzheimer’s disease treatment, but former CMS official Sean Tunis is still concerned the approach won’t meet data expectations in the planned two-year window.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts